This article was originally published in The Tan Sheet
Leaflets on drugs currently provided to patients do not provide information they value and find useful, according to researchers. In Health Technology Assessment, D.K. Raynor, Pharmacy Practice and Medicines Management Group, University of Leeds School of Healthcare, U.K., et al., say most people do not value written information they receive about drugs. Patients want to know about possible adverse events and require information to help decide whether to take a medicine. "The readability of medicines' information is important to patients, with concerns about complex language and poor visual presentation," Raynor et al. say. They included 64 papers after conducting a database search and tabulating results...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.